© Copyright - Newspaper WordPress Theme by TagDiv
Semaglutide
Also known as / Synonyms: Semaglutide, Oral Semaglutide, GLP-1 RA
GLP-1 receptor agonist improving blood glucose in type 2 diabetes and supporting chronic weight management.
Clinical Snapshot & Specifications
Approved Indications & Medical Uses
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Reduction of risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease.
- Chronic weight management in adults with obesity (BMI >= 30) or overweight (BMI >= 27) with weight-related comorbidities.
Contraindications (Do Not Use If…)
- Personal or family history of medullary thyroid carcinoma (MTC).
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to semaglutide or any excipient in the formulation.
- Type 1 diabetes mellitus or treatment of diabetic ketoacidosis.
Important Clinical Precautions & Warnings
- Risk of thyroid C-cell tumors: counsel patients on symptoms such as neck swelling, hoarseness, or dysphagia.
- Acute pancreatitis: discontinue immediately if severe persistent abdominal pain occurs.
- Hypoglycemia risk increased when combined with sulfonylureas or insulin; consider dose reduction of secretagogues.
- Acute kidney injury and dehydration risk from gastrointestinal side effects; ensure adequate hydration.
- Diabetic retinopathy complications: rapid glycemic control improvement can cause transient worsening.
- Gallbladder disease: evaluate for cholelithiasis or cholecystitis if abdominal pain develops.
Special Populations (Paediatric & Geriatric Care)
Pediatric: Safety and efficacy in children under 18 years for oral semaglutide have not been established. Elderly: No overall dose adjustments necessary; monitor renal function and hydration.
Side Effects & Adverse Reactions
Common Side Effects (Usually Mild)
Nausea, vomiting, diarrhea, abdominal pain, constipation, dyspepsia, decreased appetite, flatulence, headache, and fatigue.
Serious Side Effects — Seek Urgent Medical Care
Persistent severe abdominal pain radiating to the back (pancreatitis), neck mass/hoarseness (thyroid tumor signs), severe hypoglycemia, acute renal failure, rapid vision changes, and anaphylaxis.
Action: Discontinue medication and seek immediate medical attention or call emergency services if any serious symptom occurs.
Drug, Food & Substance Interactions
- Oral medications: delayed gastric emptying may affect absorption of orally co-administered drugs.
- Insulin and sulfonylureas (glimepiride, gliclazide): heightened hypoglycemia risk; monitor blood glucose closely.
- Levothyroxine: monitor thyroid function tests.
- Warfarin: monitor INR upon initiation and dosage adjustments.
Pregnancy & Lactation Clinical Safety
Pregnancy Safety:
ContraindicatedContraindicated during pregnancy. Discontinue semaglutide at least 2 months prior to a planned pregnancy due to long washout period. Switch to insulin therapy.
Lactation & Breastfeeding:
Generally avoidedBreastfeeding is not recommended during treatment due to lack of human milk excretion data and risk of serious adverse reactions in nursing infants.
Storage, Administration & Overdose Protocol
🌡️ Recommended Storage:
Store oral tablets (Rybelsus) at 20°C to 25°C in original blister pack to protect from moisture. Do not transfer to pill boxes. Store injection pens refrigerated at 2°C to 8°C.
⏱️ Missed Dose Protocol:
Take the oral tablet in the morning on an empty stomach with a sip of plain water (<= 120 mL) at least 30 minutes before first food, drink, or other medications. If missed, skip and resume regular schedule the next morning.
Overdose may cause severe prolonged nausea, vomiting, and hypoglycemia. Provide supportive care and medical monitoring due to long half-life (~1 week).
